Get the Stockscreener App
0.3894
5.02%
-0.0206
After Hours:
.39
0.0006
+0.15%
Akari Therapeutics Plc Adr stock is traded at $0.3894, with a volume of 500.38K.
It is down -5.02% in the last 24 hours and down -28.27% over the past month.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
See More
Previous Close:
$0.41
Open:
$0.4009
24h Volume:
500.38K
Relative Volume:
0.72
Market Cap:
$13.92M
Revenue:
-
Net Income/Loss:
$-12.29M
P/E Ratio:
-0.3745
EPS:
-1.0399
Net Cash Flow:
$-9.07M
1W Performance:
+14.87%
1M Performance:
-28.27%
6M Performance:
-66.74%
1Y Performance:
-59.01%
1-Day Range:
$0.3661
$0.47
1-Week Range:
$0.2649
$0.47
52-Week Range:
$0.2649
$1.73
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Name
Akari Therapeutics Plc Adr
Sector
Industry
Phone
(929) 274-7510
Address
401 EAST JACKSON STREET, TAMPA
Compare AKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.3894 | 14.65M | 0 | -12.29M | -9.07M | -1.0399 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Initiated | Maxim Group | Buy |
| Jan-04-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Sep-22-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-31-17 | Upgrade | Chardan Capital Markets | Sell → Neutral |
| Apr-17-17 | Reiterated | Chardan Capital Markets | Sell |
| Jul-11-16 | Initiated | Chardan Capital Markets | Sell |
View All
Akari Therapeutics Plc Adr Stock (AKTX) Latest News
Akari Therapeutics stock rises on promising pancreatic cancer drug data By Investing.com - Investing.com India
Akari Therapeutics stock rises on promising pancreatic cancer drug data - Investing.com
Wall Street analysts’ outlook for Akari Therapeutics Plc ADR (AKTX) - setenews.com
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment - Sahm
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance - Investing.com
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Release of the Next CEO Corner Segment - Sahm
Tops & Flops Stocks - sharewise.com
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - Finviz
Akari Therapeutics appoints Kameel Farag as interim CFO By Investing.com - Investing.com South Africa
Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com
[DEF 14A] Akari Therapeutics Plc Definitive Proxy Statement - Stock Titan
[S-1] Akari Therapeutics Plc Files IPO Registration Statement | AKTX SEC FilingForm S-1 - Stock Titan
Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - Sahm
Why Akari Therapeutics Plc Depositary Receipt stock appeals to analystsWall Street Watch & Verified Momentum Stock Watchlist - newser.com
[PRE 14A] Akari Therapeutics Plc Preliminary Proxy Statement - Stock Titan
Akari Therapeutics Plc ADR (AKTX) looking to reclaim success with recent performance - setenews.com
Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP - The Manila Times
AKTX SEC FilingsAkari Therapeutics Plc 10-K, 10-Q, 8-K Forms - Stock Titan
What Wall Street predicts for Akari Therapeutics Plc Depositary Receipt stock priceMarket Performance Summary & Weekly Breakout Stock Alerts - newser.com
Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com India
Form 424B5 Akari Therapeutics Plc - StreetInsider
Akari Therapeutics stock falls after $2.5 million registered offering - Investing.com
Akari Therapeutics secures $2.5 million through registered offering - Investing.com India
$2.5M raise: Akari Therapeutics to issue 3,125,000 ADSs in registered direct offering - Stock Titan
Akari Therapeutics files new patents for cancer treatment technology - Investing.com India
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 - Sahm
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
Will Akari Therapeutics Plc (Common Stock) (CLA) stock beat revenue estimatesWeekly Profit Analysis & Weekly Market Pulse Alerts - newser.com
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Sahm
A new trading data show Core Scientific Inc (CORZ) is showing positive returns. - Setenews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Institutional scanner results for ANSYS Inc.Entry Point & Verified Technical Trade Signals - newser.com
Does SRTY fit your quant trading modelPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Akari Therapeutics files patent for novel cancer treatment approach By Investing.com - Investing.com South Africa
Akari Therapeutics files patent for novel cancer treatment approach - Investing.com
Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology - Stock Titan
Is BSIIU stock reversal real or fake2025 Market Overview & Verified Swing Trading Watchlists - newser.com
Security Solutions Inc.2025 Market Outlook & Smart Money Movement Tracker - newser.com
Applying big data sentiment scoring on HLITJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan
Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan
Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Akari Therapeutics Plc Adr Stock (AKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):